14-day Premium Trial Subscription Try For FreeTry Free
Date Action Amount Person Type
Apr 06, 2023 Buy 4 000 000 Loumaye Ernest Common Shares
Feb 28, 2023 Buy 4 000 000 Loumaye Ernest Common Shares
Feb 23, 2023 Buy 250 000 Brown William Michael Employee Stock Option (right to buy)
Jan 01, 2023 Sell 0 Loumaye Ernest Common Stock
Jan 01, 2023 Buy 32 000 Mathers Edward T Stock Option (right to buy)
Jan 01, 2023 Buy 32 000 Edfjall Catarina Stock Option (right to buy)
Jan 01, 2023 Buy 32 000 Vanlent Anne Stock Option (right to buy)
Jan 01, 2023 Buy 32 000 Clancy Annette Stock Option (right to buy)
Jan 01, 2023 Buy 0 Clancy Annette Common Stock
Jan 01, 2023 Buy 715 000 O'callaghan Brian Employee Stock Option (right to buy)
Jan 01, 2023 Buy 49 140 Brown Stephanie Clare Stock Option (right to buy)
Jan 01, 2023 Buy 450 000 Brown William Michael Employee Stock Option (right to buy)
Jan 01, 2023 Buy 32 000 Loumaye Ernest Stock Option (right to buy)
Jan 01, 2023 Buy 0 Loumaye Ernest Common Stock
INSIDER POWER
47.357
Last 14 transactions
Buy: 9 624 140 | Sell: 0 (Shares)

Based on the 14 latest insides trades, we have calculated the insider power to be positive at a ratio of 47.357.

In total, the insiders bought 9 624 140 and sold 0 OBSV shares in the last 14 trades.

Click to get the best stock tips daily for free!

About ObsEva SA

ObsEva SA ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company ... OBSV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT